Carmine Diffidenti, Luisa De Martino, Antonietta Cantiello, Luigi Navas, Giovanna Elvira Granato, Fabio Olivieri, Giuseppe Iovane, Ugo Pagnini, Veeramani Maharajan, Filomena Fiorito, Fiorito, Filomena, Cantiello, Antonietta, Granato, GIOVANNA ELVIRA, Navas, Luigi, Diffidenti, Carmine, DE MARTINO, Luisa, Maharajan, Veeramani, Olivieri, Fabio, Pagnini, Ugo, and Iovane, Giuseppe
Feline herpesvirus 1 (FHV-1) is a widespread cat pathogen inducing rhinitis, conjunctivitis and corneal ulcers. To alleviate acute FHV-1-induced disease, antiviral agents are used often with antibiotics. But sometimes, these treatments, as well as conventional doses of cytokines have moderate efficacy and/or collateral effects. Herein we have investigated the effects of low dose interleukin (IL)-12 plus interferon (IFN)-gamma, prepared by Sequential Kinetic Activated (SKA), on the treatment of FHV-1 infection. Twenty-five, unvaccinated FHV-1-positive cats were recruited into a prospective, randomized, placebo-controlled, double-blinded clinical trial. Fifteen cats were treated for 6 months with oral low doses of SKA IL-12 plus IFN-gamma and 10 cats were treated with placebo. At 1, 6 and 12 months (follow-up) after the beginning of treatment, clinical assessment, PCR assay and blood count were carried out. At follow-up, in treated group, we observed significant (p